Mark Dowling Email and Phone Number
Mark Dowling's Location
Cambridge, Massachusetts, United States, United States
Mark Dowling's Contact Details
Mark Dowling work email
- Valid
- Valid
- Valid
- Valid
Mark Dowling personal email
n/a
About Mark Dowling
Mark Dowling is a Head external Innovation - Immunology at Sanofi Genzyme at Sanofi Genzyme. He possess expertise in drug discovery, pharmacology, in vitro, drug development, high throughput screening and 16 more skills.
Mark Dowling's Current Company Details
Mark Dowling Work Experience Details
-
Head External Innovation - ImmunologySanofi Genzyme Dec 2021 - PresentParis, France, Fr
-
Vice President, Translational SciencesKaleido Biosciences Nov 2019 - Dec 2021Lexington, Massachusetts, Us -
Senior Director, Head Of BiologyKaleido Biosciences May 2018 - Nov 2019Lexington, Massachusetts, Us
-
Director & Ad Interim Disease Area Head, Respiratory Disease AreaNovartis Institutes For Biomedical Research (Nibr) Jan 2017 - May 2018Basel, Baselstadt, Ch -
Senior Investigator Ii, Head Respiratory Sciences Hub (Dmp)Novartis Institutes For Biomedical Research (Nibr) Oct 2014 - Dec 2016Basel, Baselstadt, Ch
-
Senior Investigator I, Head Respiratory Sciences Hub (Dmp)Novartis Institutes For Biomedical Research (Nibr) Jun 2014 - Sep 2014Basel, Baselstadt, Ch
-
Senior Investigator INovartis Institutes For Biomedical Research (Nibr) Sep 2013 - May 2014Basel, Baselstadt, Ch• Established the Enzymology group and made key hiring and procurement decisions, directly responsible for scientific direction and long-term strategic plan of the group.• Responsible for the daily management, motivation and scientific direction of a team of thirteen research associates which provides in vitro compound profiling to drug discovery projects• Member of the Molecular Pharmacology (Compound profiling Unit) Leadership team• Project Team Head for 2 global drug discovery projects (GPCR and enzyme target). Key Achievements:The newly formed enzymology group encompass Biochemical, Biophysics (SPR, ITC, DSF) and Analytical (LC-MS/MS) methodologies to provide innovative and contemporary ligand-enzyme compound profiling. Group has extensive expertise in both compound profiling (IC50, Ki determination) and more complex mechanism of action studies (binding site determination, reversibility, tight-binding analysis). In the first year the group has provided expertise to support both target validation and clinical compound selection. Group has expertise in kinetics assays which has aided the selection of drug candidates on dissociation rates (koff) in addition to affinity parameters. I have also proposed and developed a series of novel, innovative PK:PD assays which has enabled rapid compound progression. Established an enzymology and kinetics network across NIBR to enable effective knowledge exchange and to challenge existing experimental paradigms.
-
Investigator IiiNovartis Institutes For Biomedical Research (Nibr) Nov 2010 - Aug 2013Basel, Baselstadt, Ch• Directly responsible for the daily management and development of a team of six research associates reporting to the Head of Receptor Pharmacology.• Accountable for medium-high throughput in vitro pharmacology assays (running, reporting and development) for multiple GPCR drug discovery programmes. • Provided expertise to Respiratory Disease Area on GPCR pharmacology and lipid activated (Sphingosie-1 phosphate and Lysophosphatidic Acid) receptors and enzymes.Key Achievements:Group developed several novel assays/methodologies to study the mechanism of action of ligands binding Sphingosine-1 phosphate activated receptors directly leading to the identification of a series of allosteric binders. The group was also responsible for exploring the anti-fibrotic potential of a number of targets using cell based assays (Human Lung Fibroblasts). I also secured internal funding for a post-doc dedicated to research into lung slices as a model system of fibrosis, which has supported a numerous target validation efforts.
-
Investigator IiNovartis Institutes For Biomedical Research (Nibr) Aug 2007 - Nov 2010Basel, Baselstadt, Ch
-
Head Of Allosteric PlatformAddex Pharmaceuticals Ltd Jan 2007 - Aug 2007• Head of High-Throughput Screening Laboratory, leading a team of 3 research technicians which delivered four drug-finding compound screens in 2007.• Designing, optimising and validating of multiple High Through-put Screening assays.. • Responsible for the establishment of the Allosteric Modulation Platform which provided quantitative pharmacological information on the mechanism of action of potential clinical compounds.Key Achievements:Designed functional and binding assays to identify allosteric compounds and provide Medicinal Chemists with quantitative information to further optimise compounds. Established the Addex ‘Allosteric flow-chart’ which was based on complex receptor theory models, to aid all future drug development programmes understand and optimise allosteric compounds .Initiated a series of pharmacology tutorials to improve the basic scientific understanding of allosterism for all associates -
InvestigatorNovartis Institutes For Biomedical Research (Nibr) Oct 2003 - Dec 2006Basel, Baselstadt, Ch• Integral part of a receptor pharmacology Lab as part of assay development and compound profiling team of 8-9 scientists which provided expert opinion and support for all GPCR projects. Involved in all aspects of the quantitative assessment of ligand-receptor interactions.• Directly supervised 4 Industrial Trainee students with full responsibility for their internal and personnel project work.Key Achievements:Developed several innovative radioligand binding assays to quantify complex receptor-ligand binding interaction. In particular I developed a medium throughput assay to quantify the association and dissociation rates of non-radiolabelled ligands.
Mark Dowling Skills
Drug Discovery
Pharmacology
In Vitro
Drug Development
High Throughput Screening
Assay Development
Pharmaceutical Industry
Life Sciences
Cell
Biochemistry
Cell Biology
Drug Design
Biomarkers
In Vivo
Gpcrs
Lead Change
Biotechnology
Enzymes
Fibrosis Research
Fibrosis
Enzymology
Mark Dowling Education Details
-
University Of LeicesterGpcr Pharmacology
Frequently Asked Questions about Mark Dowling
What company does Mark Dowling work for?
Mark Dowling works for Sanofi Genzyme
What is Mark Dowling's role at the current company?
Mark Dowling's current role is Head external Innovation - Immunology at Sanofi Genzyme.
What is Mark Dowling's email address?
Mark Dowling's email address is ma****@****tis.com
What schools did Mark Dowling attend?
Mark Dowling attended University Of Leicester.
What skills is Mark Dowling known for?
Mark Dowling has skills like Drug Discovery, Pharmacology, In Vitro, Drug Development, High Throughput Screening, Assay Development, Pharmaceutical Industry, Life Sciences, Cell, Biochemistry, Cell Biology, Drug Design.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial